BridgeBio Pharma
The Medical Science Liaison (MSL) is a field-based scientific expert and core member of the Medical Affairs team focused on BBP-418, a potential oral treatment for LGMD2I/R9 (FKRP-related). The role involves communicating complex scientific information to healthcare professionals, cultivating relationships with academic researchers and clinical care teams, and supporting product and territory medical planning. This position is focused on rare disease/neuromuscular therapeutic area engagement and scientific exchange.
Headquarters
Palo Alto, California, United States
Company Size
201-500 employees
Founded
2014
BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers driven by clear genetic causes. The company advances programs from target discovery through clinical development, combining human genetics and translational science with rigorous clinical trials to create targeted therapeutics. BridgeBio builds a diversified portfolio of wholly owned and partnered programs across multiple modalities and uses a venture‑style operating model to accelerate and de‑risk development. Its mission is to translate genetic insights into precision medicines for patients with high unmet medical need.
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility
6 hours ago
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
7 hours ago
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BridgeBio Pharma.
Why Is BridgeBio Pharma Stock Soaring Tuesday? - BridgeBio Pharma (NASDAQ:BBIO)
2 days ago